RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Kaken Pharmaceutical Co Stock

Kaken Pharmaceutical Co ROE 2024

Kaken Pharmaceutical Co ROE

0.06

Ticker

4521.T

ISIN

JP3207000005

In 2024, Kaken Pharmaceutical Co's return on equity (ROE) was 0.06, a -19.47% increase from the 0.07 ROE in the previous year.

Kaken Pharmaceutical Co Aktienanalyse

What does Kaken Pharmaceutical Co do?

Kaken Pharmaceutical Co Ltd is a Japanese pharmaceutical company based in Tokyo. The company was founded in 1949 and has since grown continuously to establish itself as a flagship of the Japanese pharmaceutical industry. The company specializes in the production and sale of prescription and over-the-counter drugs. However, it has also heavily focused on research and development of new medications to expand its market share. Kaken Pharmaceutical's business model is to develop and manufacture high-quality products to ensure they meet the needs and requirements of customers. This includes a wide range of medications, ranging from pain relievers and antiallergics to cosmetic products. The company categorizes its products into five different categories: dermatology, pediatrics, oncology, gastroenterology, and orthopedics. Each of these categories specializes in treating and preventing various diseases, conditions, and complaints, offering a wide range of products. Dermatology is one of the key divisions of Kaken Pharmaceutical. The company offers medications for treating skin conditions such as psoriasis, eczema, dermatitis, and acne. One of its most well-known products is the anti-acne medication Isotretinoin. It works by reducing sebum production, thus reducing inflammation and pore blockage. Kaken Pharmaceutical's pediatrics products focus on treating children. Syrups and drops for symptom relief of colds, coughs, fevers, and diarrhea are among the products offered. In this category, Kaken Pharmaceutical also provides medications for treating children with ADHD. Oncology medications are offered by Kaken Pharmaceutical under the name "Kaken Pharma." These products are intended for the treatment of cancer diseases such as lung, breast, and stomach cancer. The company is constantly striving to improve its research and development to make cancer treatment more effective and efficient. The gastroenterology category focuses on treating digestive disorders such as heartburn, reflux, and gastric ulcers. Kaken Pharmaceutical has introduced several products, including drugs that inhibit stomach acid, which are offered in the form of tablets and granules. Orthopedic medications from Kaken Pharmaceutical are used to treat pain and inflammation of the skeletal system, such as relieving joint pain, arthritis, and osteoporosis. The most well-known product is the pain reliever Ibuprofen, which is available for both oral and topical use. In conclusion, Kaken Pharmaceutical Co Ltd is a company committed to meeting the medical and cosmetic needs of customers. Each product is carefully developed and manufactured to ensure the highest quality and effectiveness. With its wide range of products and research efforts, the company is an important player in the global pharmaceutical market. Kaken Pharmaceutical Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROE Details

Decoding Kaken Pharmaceutical Co's Return on Equity (ROE)

Kaken Pharmaceutical Co's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Kaken Pharmaceutical Co's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Kaken Pharmaceutical Co's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Kaken Pharmaceutical Co’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Kaken Pharmaceutical Co stock

What is the ROE (Return on Equity) of Kaken Pharmaceutical Co this year?

The ROE of Kaken Pharmaceutical Co this year is 0.06 undefined.

How has the Return on Equity (ROE) of Kaken Pharmaceutical Co developed compared to the previous year?

The ROE of Kaken Pharmaceutical Co has increased by -19.47% decreased compared to the previous year.

What impact does a high ROE (Return on Equity) have on investors of Kaken Pharmaceutical Co?

A high ROE indicates that Kaken Pharmaceutical Co generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.

What impact does a low ROE (Return on Equity) have on investors of Kaken Pharmaceutical Co?

A low ROE can indicate that Kaken Pharmaceutical Co is having difficulties monetizing its investments successfully and can be a negative signal for investors.

How does a change in the ROE (Return on Equity) of Kaken Pharmaceutical Co affect the company?

A change in ROE (Return on Equity) of Kaken Pharmaceutical Co can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.

How to calculate the ROE (Return on Equity) of Kaken Pharmaceutical Co?

The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.

Which factors influence the ROE (Return on Equity) of Kaken Pharmaceutical Co?

Some factors that can influence Kaken Pharmaceutical Co's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.

What strategic measures can take to improve the ROE (Return on Equity)?

To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.

How much dividend does Kaken Pharmaceutical Co pay?

Over the past 12 months, Kaken Pharmaceutical Co paid a dividend of 115 JPY . This corresponds to a dividend yield of about 2.63 %. For the coming 12 months, Kaken Pharmaceutical Co is expected to pay a dividend of 118.9 JPY.

What is the dividend yield of Kaken Pharmaceutical Co?

The current dividend yield of Kaken Pharmaceutical Co is 2.63 %.

When does Kaken Pharmaceutical Co pay dividends?

Kaken Pharmaceutical Co pays a quarterly dividend. This is distributed in the months of October, April, October, April.

How secure is the dividend of Kaken Pharmaceutical Co?

Kaken Pharmaceutical Co paid dividends every year for the past 23 years.

What is the dividend of Kaken Pharmaceutical Co?

For the upcoming 12 months, dividends amounting to 118.9 JPY are expected. This corresponds to a dividend yield of 2.71 %.

In which sector is Kaken Pharmaceutical Co located?

Kaken Pharmaceutical Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Kaken Pharmaceutical Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Kaken Pharmaceutical Co from 12/1/2024 amounting to 40 JPY, you needed to have the stock in your portfolio before the ex-date on 9/27/2024.

When did Kaken Pharmaceutical Co pay the last dividend?

The last dividend was paid out on 12/1/2024.

What was the dividend of Kaken Pharmaceutical Co in the year 2023?

In the year 2023, Kaken Pharmaceutical Co distributed 150 JPY as dividends.

In which currency does Kaken Pharmaceutical Co pay out the dividend?

The dividends of Kaken Pharmaceutical Co are distributed in JPY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Kaken Pharmaceutical Co

Our stock analysis for Kaken Pharmaceutical Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Kaken Pharmaceutical Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.